0001213900-26-016458
SEC filingAdvanced Biomed Inc. (ADVB) reported a significant turnaround for the fiscal second quarter ended December 31, 2025, posting a net income of $6.9 million compared to historical losses. This profitability was driven almost entirely by a $7.3 million gain on the disposal of subsidiaries, contrasting with modest operating expenses of $397K. The company reported zero revenue for the period. Operating activities utilized $872K in cash, though financing activities provided $763K. The balance sheet reflects total assets of $10.9M against total liabilities of $1.4M, resulting in stockholders' equity of $9.5M. The disposal of subsidiaries marks a strategic pivot, significantly bolstering the company's financial position despite continued losses from discontinued operations of $144K. The company maintains a cash position of $2.6M from continuing operations.
For the fiscal second quarter ended December 31, 2025, Advanced Biomed Inc. reported a net income of $6.9 million, a significant shift attributed primarily to non-operational activities. The company recognized a substantial gain of $7.3 million from the disposal of subsidiaries. This one-time event offset the total operating expenses of $397K, which included $186K in research and development and $210K in general and administrative expenses. The income from continuing operations was reported at $7.0M. However, the company incurred a loss of $144K from discontinued operations, net of tax. No revenue was generated during this period. The weighted average number of shares outstanding remained steady at 21.6 million.
The company did not report any revenue for the period ending December 31, 2025. Consequently, there is no segment breakdown, geographic mix, or revenue growth analysis to present. The financial results are entirely driven by cost management and strategic financial transactions, specifically the disposal of subsidiaries, rather than core business operations or sales activities.
With zero revenue, traditional margin metrics such as gross margin and operating margin are not applicable. The company operated at a loss before the extraordinary gain. Total operating expenses were $397K. The net profit margin is technically positive due to the $7.3M gain on disposal of subsidiaries, but this does not reflect operational profitability. The loss from discontinued operations ($144K) further highlights that certain divested units were unprofitable. Interest income contributed a minor $9K to other income.
The balance sheet shows total assets of $10.9M, comprised mainly of $2.6M in cash and $8.1M in prepaid expenses and other current assets. Total liabilities stood at $1.4M, resulting in stockholders' equity of $9.5M. Cash flow from operating activities was negative, using $872K, largely due to changes in operating assets and discontinued operations. Financing activities provided $763K, primarily from proceeds related to related parties. The company holds $2.6M in cash from continuing operations, with an additional $6K attributed to discontinued operations.
The filing does not contain specific forward-looking statements or management guidance regarding future revenue or strategic initiatives beyond the reported financial figures. The significant gain from subsidiary disposal suggests a restructuring or strategic pivot, but explicit details on future operations or risk factors were not provided in the financial data section. Investors should monitor future filings for updates on the utilization of the $2.6M cash position and the strategic direction of the continuing operations.